Research and application of the SARS-CoV-2 vaccine based on adenovirus vector technology platform.
10.3760/cma.j.cn112150-20230419-00309
- VernacularTitle:基于腺病毒载体技术平台的新型冠状病毒疫苗研发和应用进展
- Author:
Ying ZHANG
1
;
Wen Zhou YU
2
;
Zun Dong YIN
2
;
Tong Zhan WANG
3
;
Xiao Dong SUN
4
;
Ai Qiang XU
3
Author Information
1. Tianjin Center for Disease Control and Prevention, Tianjin 300011, China.
2. National Immunization Programme, China Center for Disease Control and Prevention, Beijing 100050, China.
3. Shandong Center for Disease Control and Prevention/Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan 250014, China.
4. Shanghai Center for Disease Control and Prevention, Shanghai 201204, China.
- Publication Type:Journal Article
- MeSH:
Humans;
COVID-19 Vaccines;
Pandemics/prevention & control*;
COVID-19/prevention & control*;
SARS-CoV-2/genetics*;
Viral Vaccines/genetics*;
Adenoviridae/genetics*;
Technology
- From:
Chinese Journal of Preventive Medicine
2023;57(7):1082-1095
- CountryChina
- Language:Chinese
-
Abstract:
During the global efforts to prevent and control the COVID-19 pandemic, extensive research and development of SARS-CoV-2 vaccines using various technical approaches have taken place. Among these, vaccines based on adenovirus vector have gained substantial knowledge and experience in effectively combating potential emerging infectious diseases, while also providing novel ideas and methodologies for vaccine research and development (R&D). This comprehensive review focuses on the adenovirus vector technology platform in vaccine R&D, emphasizing the importance of mucosal immunity induced by adenoviral vector-based vaccine for COVID-19 prevention. Furthermore, it analyzes the key technical challenges and obstacles encountered in the development of vaccines based on the adenovirus vector technology platform, with the aim of providing valuable insights and references for researchers and professionals in related fields.
